Principles of the activin receptor signaling pathway and its inhibition

Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity

(2021) Steven B. Heymsfield et al.   JAMA Network Open

Structural basis for specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015

(2020) Kevin B Dagbay et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

(2020) Pierre Fenaux et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia

(2020) M. Domenica Cappellini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults

(2020) Daniel Rooks et al.   JAMA Network Open

Compression of morbidity in a progeroid mouse model through the attenuation of myostatin/activin signalling

(2019) Khalid Alyodawi et al.   Journal of Cachexia Sarcopenia and Muscle

A follistatin-based molecule increases muscle and bone mass without affecting the red blood cell count in mice

(2019) Andreas Lodberg et al.   FASEB JOURNAL

Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of beta-thalassemia

(2019) Amaliris Guerra et al.   BLOOD

Steady-state and regenerative hematopoiesis occur normally in mice in the absence of GDF11

(2019) Jill M. Goldstein et al.   BLOOD

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial

(2019) Michael G Hanna et al.   LANCET NEUROLOGY

Sarcopenia as a mortality predictor in community-dwelling older adults: a comparison of the diagnostic criteria of the European Working Group on Sarcopenia in Older People

(2019) Nathalia Perleberg Bachettini et al.   EUROPEAN JOURNAL OF CLINICAL NUTRITION

P.126SRK-015, a fully human monoclonal antibody inhibiting myostatin activation, offers sustained target engagement across multiple species, including humans

(2019) A. Kalra et al.   NEUROMUSCULAR DISORDERS

Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease

(2019) R. S. Pearsall et al.   Scientific Reports

Sarcopenia in COPD: a systematic review and meta-analysis

(2019) Elizabeth Benz et al.   European Respiratory Review

What can we learn from ineffective erythropoiesis in thalassemia?

(2018) Paraskevi Rea Oikonomidou et al.   BLOOD REVIEWS

A soluble activin type IIA receptor mitigates the loss of femoral neck bone strength and cancellous bone mass in a mouse model of disuse osteopenia

(2018) Andreas Lodberg et al.   BONE

Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes

(2018) Tania Garito et al.   CLINICAL ENDOCRINOLOGY

Tolloid cleavage activates latent GDF8 by priming the pro‐complex for dissociation

(2018) Viet Q Le et al.   EMBO JOURNAL

Myogenic regulatory factors: The orchestrators of myogenesis after 30 years of discovery

(2018) Hasan A Asfour et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Locally acting ACE-083 increases muscle volume in healthy volunteers

(2018) Chad E. Glasser et al.   MUSCLE & NERVE

Inhibin βE (INHBE) is a possible insulin resistance-associated hepatokine identified by comprehensive gene expression analysis in human liver biopsy samples

(2018) Masakazu Sugiyama et al.   PLoS One

Molecular characterization of latent GDF8 reveals mechanisms of activation

(2018) Ryan G. Walker et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Sarcopenia: a chronic complication of type 2 diabetes mellitus

(2018) Heloísa Trierweiler et al.   Diabetology & Metabolic Syndrome

Blocking extracellular activation of myostatin as a strategy for treating muscle wasting

(2018) M. Pirruccello-Straub et al.   Scientific Reports

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial

(2018) Rami Komrokji et al.   Lancet Haematology

OUP accepted manuscript

(2018)   AGE AND AGEING

Normal and pathologic erythropoiesis in adults: from gene regulation to targeted treatment concepts

(2018) Peter Valent et al.   HAEMATOLOGICA

CMT AND NEUROGENIC DISEASE

(2018) M. Shy et al.   NEUROMUSCULAR DISORDERS

FSHD / OPMD / EDMD / DMI

(2018) J. Statland et al.   NEUROMUSCULAR DISORDERS

LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial

(2018) Talia Golan et al.   Journal of Cachexia Sarcopenia and Muscle

Follistatin-288-Fc Fusion Protein Promotes Localized Growth of Skeletal Muscle

(2018) Roselyne Castonguay et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Biochemical and Cellular Analysis Reveals Ligand Binding Specificities, a Molecular Basis for Ligand Recognition, and Membrane Association-dependent Activities of Cripto-1 and Cryptic

(2017) Senem Aykul et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study

(2017) Daniel Rooks et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

(2017) Uwe Platzbecker et al.   LANCET ONCOLOGY

Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption

(2017) N. Doyle et al.   OSTEOPOROSIS INTERNATIONAL

Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy

(2017) Frederic Morvan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Activin A more prominently regulates muscle mass in primates than does GDF8

(2017) Esther Latres et al.   Nature Communications

A muscle-specific MuRF1-E2 network requires stabilization of MuRF1-E2 complexes by telethonin, a newly identified substrate

(2017) Cécile Polge et al.   Journal of Cachexia Sarcopenia and Muscle

Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy

(2017) Daniel S. Rooks et al.   Journal of Cachexia Sarcopenia and Muscle

A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys

(2017) Michael St. Andre et al.   Skeletal Muscle

Sarcopenia in patients with chronic kidney disease not yet on dialysis: Analysis of the prevalence and associated factors

(2017) Viviane Angelina de Souza et al.   PLoS One

Quantification of GDF11 and Myostatin in Human Aging and Cardiovascular Disease

(2016) Marissa J. Schafer et al.   Cell Metabolism

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial

(2016) Craig Campbell et al.   MUSCLE & NERVE

GDF11 decreases bone mass by stimulating osteoclastogenesis and inhibiting osteoblast differentiation

(2016) Weiqing Liu et al.   Nature Communications

TGF-  signaling in the control of hematopoietic stem cells

(2015) U. Blank et al.   BLOOD

GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration

(2015) Marc A. Egerman et al.   Cell Metabolism

Rapid Activation of Bone Morphogenic Protein 9 by Receptor-mediated Displacement of Pro-domains

(2015) Yvonne Kienast et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting

(2015) R. C. Smith et al.   MOLECULAR CANCER THERAPEUTICS

Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice

(2015) Berno Dankbar et al.   NATURE MEDICINE

Structure of bone morphogenetic protein 9 procomplex

(2015) Li-Zhi Mi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies

(2015) Haralambos Raftopoulos et al.   SUPPORTIVE CARE IN CANCER

Evaluation of follistatin as a therapeutic in models of skeletal muscle atrophy associated with denervation and tenotomy

(2015) Patricio V. Sepulveda et al.   Scientific Reports

Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial

(2015) Clemens Becker et al.   Lancet Diabetes & Endocrinology

Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice

(2015) Esther Latres et al.   Skeletal Muscle

Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia

(2015) Emmanuelle Tillet et al.   Frontiers in Genetics

RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice

(2014) Jacqueline M. Langdon et al.   AMERICAN JOURNAL OF HEMATOLOGY

A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers

(2014) Kenneth M. Attie et al.   AMERICAN JOURNAL OF HEMATOLOGY

An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin

(2014) Soraya Carrancio et al.   BRITISH JOURNAL OF HAEMATOLOGY

Sotatercept in patients with osteolytic lesions of multiple myeloma

(2014) Kudrat M. Abdulkadyrov et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pharmacological Inhibition of Myostatin and Changes in Lean Body Mass and Lower Extremity Muscle Size in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

(2014) Desmond Padhi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia

(2014) Michael Dussiot et al.   NATURE MEDICINE

Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis

(2014) Rajasekhar N V S Suragani et al.   NATURE MEDICINE

Treatment of sporadic inclusion body myositis with bimagrumab

(2014) A. A. Amato et al.   NEUROLOGY

Vascular and Neurogenic Rejuvenation of the Aging Mouse Brain by Young Systemic Factors

(2014) L. Katsimpardi et al.   SCIENCE

miR-21 mediates hematopoietic suppression in MDS by activating TGF-  signaling

(2013) T. D. Bhagat et al.   BLOOD

Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women

(2013) Matthew L. Sherman et al.   JOURNAL OF CLINICAL PHARMACOLOGY

An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy

(2013) E. Lach-Trifilieff et al.   MOLECULAR AND CELLULAR BIOLOGY

A Novel Therapeutic Approach to Treating Obesity through Modulation of TGFβ Signaling

(2012) Alan Koncarevic et al.   ENDOCRINOLOGY

Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap

(2012) Camelia Iancu-Rubin et al.   EXPERIMENTAL HEMATOLOGY

Specificity and Structure of a High Affinity Activin Receptor-like Kinase 1 (ALK1) Signaling Complex

(2012) Sharon A. Townson et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Role of satellite cells versus myofibers in muscle hypertrophy induced by inhibition of the myostatin/activin signaling pathway

(2012) S.-J. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting the Activin Type IIB Receptor to Improve Muscle Mass and Function in the mdx Mouse Model of Duchenne Muscular Dystrophy

(2011) Emidio E. Pistilli et al.   AMERICAN JOURNAL OF PATHOLOGY

Myostatin promotes the wasting of human myoblast cultures through promoting ubiquitin-proteasome pathway-mediated loss of sarcomeric proteins

(2011) Sudarsanareddy Lokireddy et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Reducing Noninfectious Risks of Blood Transfusion

(2011) Brian M. Gilliss et al.   ANESTHESIOLOGY

Myostatin induces autophagy in skeletal muscle in vitro

(2011) Jen Y. Lee et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Generation of a Specific Activin Antagonist by Modification of the Activin A Propeptide

(2011) Yogeshwar Makanji et al.   ENDOCRINOLOGY

Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease

(2011) Liping Zhang et al.   FASEB JOURNAL

Bone mineralization

(2011) Ermanno Bonucci   Frontiers in Bioscience-Landmark

Building strong bones: molecular regulation of the osteoblast lineage

(2011) Fanxin Long   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The role and regulation of MAFbx/atrogin-1 and MuRF1 in skeletal muscle atrophy

(2011) Victoria C. Foletta et al.   PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY

Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors

(2011) Mark J. Anderton et al.   TOXICOLOGIC PATHOLOGY

Identification and analysis of type II TGF-  receptors in BMP-9-induced osteogenic differentiation of C3H10T1/2 mesenchymal stem cells

(2010) N. Wu et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys

(2010) Sutada Lotinun et al.   BONE

Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival

(2010) Xiaolan Zhou et al.   CELL

A Soluble Activin Receptor Type IIB Prevents the Effects of Androgen Deprivation on Body Composition and Bone Health

(2010) Alan Koncarevic et al.   ENDOCRINOLOGY

Characterization of the Ligand Binding Functionality of the Extracellular Domain of Activin Receptor Type IIB

(2010) Dianne Sako et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size

(2009) Anne Ulrike Trendelenburg et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Smad2 and 3 transcription factors control muscle mass in adulthood

(2009) Roberta Sartori et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Stimulation of skeletal muscle myofibrillar protein synthesis, p70 S6 kinase phosphorylation, and ribosomal protein S6 phosphorylation by inhibition of myostatin in mature mice

(2009) Stephen Welle et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding

(2009) Jennifer N Cash et al.   EMBO JOURNAL

Hematocrit and risk of venous thromboembolism in a general population. The Tromso study

(2009) S. K. Braekkan et al.   HAEMATOLOGICA

Bisphosphonates: Mechanism of Action and Role in Clinical Practice

(2009) Matthew T. Drake et al.   MAYO CLINIC PROCEEDINGS

Measurement of myostatin concentrations in human serum: Circulating concentrations in young and older men and effects of testosterone administration

(2009) Kishore M. Lakshman et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Activin C Antagonizes Activin A in Vitro and Overexpression Leads to Pathologies in Vivo

(2008) Elspeth Gold et al.   AMERICAN JOURNAL OF PATHOLOGY

A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy

(2008) Kathryn R. Wagner et al.   ANNALS OF NEUROLOGY

Osteoclast lineage and function

(2008) H. Kalervo Väänänen et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Inhibition of the TGF-  receptor I kinase promotes hematopoiesis in MDS

(2008) L. Zhou et al.   BLOOD

Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study of ACE-011 (ActRIIA-IgG1) in Postmenopausal Women*

(2008) Jon Ruckle et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Proteomic Identification and Functional Validation of Activins and Bone Morphogenetic Protein 11 as Candidate Novel Muscle Mass Regulators

(2008) Tatyana A. Souza et al.   MOLECULAR ENDOCRINOLOGY

Single muscle fiber contractile properties in adults with muscular dystrophy treated with MYO-029

(2008) Lisa S. Krivickas et al.   MUSCLE & NERVE

A soluble activin Type IIA receptor induces bone formation and improves skeletal integrity

(2008) R. S. Pearsall et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anabolic steroids in COPD: a review and preliminary results of a randomized trial

(2008) S Sharma et al.   Chronic Respiratory Disease

Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure

(2007) Karien van der Putten et al.   Nature clinical practice. Nephrology